Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23937225 | 0.82 | POLB (0.49) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL10304450 | 0.72 | POLB (0.62) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL19002339 | 0.69 | LMNA (0.60) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL18997087 | 0.69 | LMNA (0.56) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL8363998 | 0.69 | POLB (0.53) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL11748962 | 0.68 | RAB9A (0.39) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL11684372 | 0.67 | POLB (0.51) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL8363999 | 0.66 | POLB (0.50) | KMT2APOLBRAB9ASMN1; SMN2MAPT | |
| SCHEMBL7399930 | 0.66 | HTR2B (0.41) | POLB | |
| SCHEMBL10246092 | 0.66 | POLB (0.58) | KMT2APOLBSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322416-A1 | ANTIVIRAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322416-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, CD4 | KMT2A 3667/4885POLB 1804/4885RAB9A 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.